

EU Vaccination Roadmap, 2018-2022

In case you were skeptical about EU vaccination passport planning, here are the receipts

By [Dr. Robert Malone](#)

Global Research, November 08, 2022

[Who is Robert Malone](#) 7 November 2022

Region: [Europe](#)


Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the **Translate Website** button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

Just who are the stakeholders that are being consulted?

ROADMAP ON VACCINATION Last update: Q3 2022		 European Commission 1				
ROADMAP FOR THE IMPLEMENTATION OF ACTIONS BY THE EUROPEAN COMMISSION BASED ON THE COMMISSION COMMUNICATION AND THE COUNCIL RECOMMENDATION ON STRENGTHENING COOPERATION AGAINST VACCINE PREVENTABLE DISEASES						
ACTIONS	TIMELINES AND DELIVERABLES					
	2018	2019	2020	2021	2022	
Examine the feasibility of developing a common vaccination card/passport for EU citizens (that takes into account potentially different national vaccination schedules and), that is compatible with electronic immunisation information systems and recognised for use across borders, without duplicating work at national level.		Feasibility study for the development of a common EU vaccination card - completed -publication pending			Commission proposal for a common vaccination card/ passport for EU citizens - considered delivered in the format of Commission proposal for Regulation on the European Health Data Space: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A52022PC0197	
	CR 16 and CC*					
Produce on a regular basis a Report on the State of Vaccine Confidence in the EU , to monitor attitudes to vaccination. Based on that report and taking into account related work by WHO, present guidance that can support Member States in countering vaccine hesitancy.		State of Vaccine Confidence in the EU 2020. Follow up of study published in October 2018. See https://health.ec.europa.eu/vaccination/state-vaccine-confidence_en	Guidance on countering vaccine hesitancy tailored to specific needs identified by the Member States and/ or vaccine specific issues - ECDC report on vaccine hesitancy against HPV: https://www.ecdc.europa.eu/sites/default/files/documents/Guidance-on-HPV-vaccination-in-EU-countries2020-03-30.pdf			
	CR 17 and CC	Special Eurobarometer - Europeans' attitudes towards vaccination: https://health.ec.europa.eu/system/files/2019-04/20190426-special-eurobarometer-sp488_en_0.pdf				

* Basis for action:
CR for Council Recommendation and the number of the Recommendation in the legal text. CC for Commission Communication

[Click here to enlarge.](#)

ACTIONS	TIMELINES AND DELIVERABLES				
	2018	2019	2020	2021	2022
Develop guidance to overcome the legal and technical barriers impeding the interoperability of national immunisation information systems, having due regard to rules on personal data protection, as set out in the Commission Communication on enabling the digital transformation of health and care in the Digital Single Market, empowering citizens and building a healthier society.				Guidance on overcoming legal (and technical) barriers to the interoperability of national immunisation information systems - considered delivered in the format of the the Commission Recommendation on a European Electronic Health Record exchange format (https://digital-strategy.ec.europa.eu/en/library/recommendation-european-electronic-health-record-exchange-format) and the guideline for an electronic Patient Summary (https://health.ec.europa.eu/system/files/2021-07/ehn_guidelines_patientsummary_en_0.pdf)	
	CR 21 and CC				
Continue to support research and innovation through the EU framework programmes for Research and Innovation for the development of safe and effective new vaccines, and the optimisation of existing vaccines.	Projects funded under Horizon 2020 and Horizon Europe - delivered (action of continuous character). See https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/coronavirus-research-and-innovation/vaccines_en https://ec.europa.eu/info/research-and-innovation/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en and https://ec.europa.eu/info/research-and-innovation/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-europe_en				
	CR 22				
Strengthen existing partnerships and collaboration with international actors and initiatives, such as the WHO and its Strategic Advisory Group of Experts on Immunization (SAGE), the European Technical Advisory Group of Experts on Immunization (ETAGE), the Global Health Security Initiative and Agenda processes (Global Health Security Initiative, Global Health Security Agenda), Unicef and financing and research initiatives like Gavi, CEPI, GloPID-R and JPIAMR (the Joint Programming Initiative on Antimicrobial Resistance).		Global Vaccination Summit organised by the European Commission in cooperation with the World Health Organization. Delivered on 12 September 2019. Outcome: https://health.ec.europa.eu/system/files/2019-11/10actions_en_0.pdf			
	CR 23 and CC				

[Click here to enlarge.](#)

ACTIONS	TIMELINES AND DELIVERABLES				
	2018	2019	2020	2021	2022
Develop evidence-based tools and guidance at EU level in order to support countries to anticipate, pre-empt or respond to crisis situations.	Report on previous experience about vaccine shortages and responses of EU countries - delivered by the European Joint Action Work Package 6: https://eu-jav.com/				
	Guidelines on procedures to estimate vaccine needs and procurement in the EU - delivered by the European Joint Action on Vaccination - Work Package 6: https://eu-jav.com/				
	Report on the financial mechanism for joint procurement based on an evaluation of the financing mechanisms in different countries - delivered by the European Joint Action on Vaccination - Work Package 6: https://eu-jav.com/				
	Establish a vaccine network with Member States to leverage the sustainability of activities of the joint action beyond the project - delivered by the European Joint Action for Vaccination Work Package 4: https://eu-jav.com/				
	Develop an "integration of outcomes of the joint action into national policies & sustainability" plan to strive towards a converging vaccine agenda for the most commonly used vaccines at EU level - delivered by the European Joint Action on Vaccination Work Package 4: https://eu-jav.com/				
	Overview of EU-level and national legal and technical frameworks and operational criteria for decision-making on vaccination policies and available (EU and national) platforms - delivered by the European Joint Action on Vaccination Work Package 4: https://eu-jav.com/				
	Survey on the range of attributable costs used for the most recent MS-National Immunisation Technical Advisory Groups (NITAGs) evaluations available - delivered by the European Joint Action on Vaccination Work Package 4: https://eu-jav.com/				
	Pilot of a technical collaboration to establish an active cooperation structure across NITAGs - delivered by the European Joint Action on Vaccination Work Package 4: https://eu-jav.com/				
	Pilots to provide an overview about the evidence-base of national immunisation programmes - delivered by the European Joint Action on Vaccination Work Package: https://eu-jav.com/				
	CC				
Counter online vaccine misinformation and develop evidence-based information tools and guidance to support Member States in responding to vaccine hesitancy, in line with the Commission Communication on tackling online disinformation.	Countering online vaccine misinformation, taking into account the Commission Communication on tackling online disinformation - ECDC report on countering online vaccine misinformation in the EU/EEA: https://www.ecdc.europa.eu/sites/default/files/documents/Countering-online-vaccine-misinformation-in-the-EU-EEA.pdf				
	Online and offline promotion of the new information tools (through social media, search engine optimisation, specialised media) in particular towards the sectors of health care, education, social services, media - toolset for online use: https://drive.google.com/drive/folders/1XkWCXu2541Cth2BRvWHozTbHkiv2Bc				
	CR 9c and CC				

[Click here to enlarge.](#)

ACTIONS

TIMELINES AND DELIVERABLES

	2018	2019	2020	2021	2022
<p>Consider developing a virtual European data warehouse on vaccine needs and, if applicable, offerable stocks, to facilitate the voluntary exchange of information on available supplies, possible surpluses and global shortages of essential vaccines.</p> <p>CR 14a and CC</p>	<p>Develop common principles for vaccine demand forecasting - delivered by the European Joint Action for Vaccination Work Package 6: https://eu-jav.com/</p> <p>Development of a concept for a regional or European data warehouse for (virtual stockpiling and vaccine management) needs - delivered by the European Joint Action Work Package 6: https://eu-jav.com/</p>				<p>Develop a virtual European data warehouse on vaccine needs and, if applicable, offerable stocks, to facilitate the voluntary exchange of information on available supplies, possible surpluses and global shortages of essential vaccines - considered delivered due to the set-up of DG HERA. See https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en</p>
	<p>Explore feasibility of physical stockpiling and engage in a dialogue with vaccine producing companies on a mechanism to facilitate the stockpiling and availability of vaccines in case of outbreaks, taking into account global shortages of essential vaccines.</p> <p>CR 14 b and c and CC</p>		<p>Study exploring the feasibility of and identifying options for physical stockpiling of vaccines - considered delivered due to the set-up of DG HERA. See https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en</p>		
	<p>Consider developing a concept for a mechanism for exchanging vaccine supplies from one Member State to another in case of an outbreak, improving the links between supply and demand for vaccines.</p> <p>CR 14 b and c and CC</p>		<p>Concept for a mechanism for exchanging vaccine supplies from one Member State to another in case of an outbreak - considered delivered due to the set-up of DG HERA. See https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en</p>		

[Click here to enlarge.](#)

ACTIONS

TIMELINES AND DELIVERABLES

	2018	2019	2020	2021	2022
<p>Consider, jointly with stakeholders, in particular with the vaccine-manufacturing industry, which has a key role in meeting these aims, possibilities for improving EU manufacturing capacity, ensuring continuity of supply and ensuring diversity of suppliers.</p> <p>CR 14d</p>			<p>Conference on improving EU manufacturing capacity and ensuring continuity of supply - considered delivered due to the set-up of DG HERA. See https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en</p>		
<p>Exploit the possibilities of joint procurement of vaccines or antitoxins to be used in cases of pandemics, unexpected outbreaks and in case of small vaccine demand (small number of cases or very specific populations to be covered).</p> <p>CR 14e</p>		<p>Joint procurement of pandemic influenza vaccine Framework contracts signed in March 2019. See https://health.ec.europa.eu/vaccination/influenza_en</p>			
<p>Support the EU Official Medicines Control Laboratories network and its work to ensure that vaccines placed on the EU market are of high quality.</p> <p>CR 14f</p>		<p>Meeting with the EU Official Medicines Control Laboratories network - delivered</p>			
<p>Monitor compliance with the obligation of continuous supply of medicines placed on marketing authorisation holders (Article 81 of Directive 2001/83/EC) and explore ways to enhance compliance with that obligation.</p> <p>CR 14g</p>		<p>Examination whether this article has been implemented in full in national legislation - delivered</p>			
<p>Consider facilitating –together with EMA- early dialogue with developers, national policy-makers and regulators in order to support the authorisation of innovative vaccines, including for emerging health threats.</p> <p>CR 14h</p>		<p>Actions to facilitate early dialogue with developers, national policy-makers and regulators in order to support the authorisation of innovative vaccines, including for emerging health threats - considered delivered due to the set-up of DG HERA. See https://ec.europa.eu/info/strategy/priorities-2019-2024/promoting-our-european-way-life/european-health-union_en</p>			

[Click here to enlarge.](#)

ACTIONS	TIMELINES AND DELIVERABLES				
	2018	2019	2020	2021	2022
Reinforce existing partnerships and research infrastructures, and establish new ones, including for clinical trials. CR 15a and CC			Establishment of research networks for clinical trials and fostering collaborative research infrastructures and/or programmes e.g. clinical trial network to be established. ECRIN, support to CEPI, EDCTP-2, etc. - delivered (action of continuous character). See in particular https://vaccelerate.eu/		
Seek consensus on unmet population needs and agreed priorities for vaccines that can be used to inform future vaccine research funding programmes at national and EU level, including leveraging the advantages of the Coalition for Epidemic Preparedness Innovations (CEPI) and the Global Research Collaboration for Infectious diseases Preparedness (GloPID-R). CR 15b and CC	Roadmap of unmet population needs and agreed priorities for vaccines - delivered by the European Joint Action on Vaccination Work Package 7: https://eu-jav.com/				
	Agree on a subset of vaccines as regards research priorities - delivered by the European Joint Action on Vaccination Work Package 7: https://eu-jav.com/				
	Define a concept framework for decision-making on research priorities for an agreed subset of vaccines - delivered by the European Joint Action on Vaccination Work Package 7: https://eu-jav.com/				
	Report on a proposal for shared funding mechanisms based on an analysis of funding gaps and hurdles for cooperation among funders - delivered by the European Joint Action on Vaccination Work Package 7: https://eu-jav.com/		Define a proposal for an annual list of EU vaccine research priorities - delivered by the European Joint Action on Vaccination Work Package 7: https://eu-jav.com/		
Consider investing in behavioural and social science research on the determinants of vaccine hesitancy across different subgroups of the population and healthcare workers. CR 15c and CC			Set of actions funded by Horizon 2020 and actions undertaken by ECDC to address low-vaccine uptake, and behavioural study on vaccination to identify determinants of vaccine hesitancy across different subgroups of the population and health workers - delivered (action of continuous character). See https://ec.europa.eu/info/research-and-innovation/funding/funding-opportunities/funding-programmes-and-open-calls/horizon-2020_en . Action linked to "Guidance on increasing access to vaccination for disadvantaged and socially excluded groups - publication pending - expected Q4 2022"		
Report on a regular basis, on progress in implementing the Recommendation based on indicators agreed with Member States and on information from other relevant sources. CR 24			Biannual progress report on the implementation of the Council Recommendation - ongoing - study planned for Q3 2023		

[Click here to enlarge.](#)


The future is here.

What we all should be asking is what do they have planned for 2023 and beyond or even to 2030?

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Featured image is from the author



The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”

ISBN: 978-0-9879389-3-0, **Year:** 2022, **PDF Ebook,** **Pages:** 164, 15 Chapters

Price: \$11.50

[Purchase directly from the Global Research Online Store](#)

You may also purchase directly at **[DonorBox “Worldwide Corona Crisis” Campaign Page!](#)** (NOTE: **User-friendly**)

The original source of this article is [Who is Robert Malone](#)
Copyright © [Dr. Robert Malone](#), [Who is Robert Malone](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: **[Dr. Robert Malone](#)**

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca